Levels of retinol and retinoic acid in pancreatic cancer, type-2 diabetes and chronic pancreatitis.

all-trans-retinoic-acid chronic pancreatitis pancreatic ductal adenocarcinoma type-2 diabetes mellitus vitamin A

Journal

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
ISSN: 1804-7521
Titre abrégé: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
Pays: Czech Republic
ID NLM: 101140142

Informations de publication

Date de publication:
06 Dec 2023
Historique:
medline: 7 12 2023
pubmed: 7 12 2023
entrez: 7 12 2023
Statut: aheadofprint

Résumé

Retinoids participate in multiple key processes in the human body e.g., vision, cell differentiation and embryonic development. There is growing evidence of the relationship between retinol, its active metabolite- all-trans retinoic acid (ATRA) - and several pancreatic disorders. Although low levels of ATRA in pancreatic ductal adenocarcinoma (PDAC) tissue have been reported, data on serum levels of ATRA in PDAC is still limited. The aim of our work was to determine serum concentrations of retinol and ATRA in patients with PDAC, type-2 diabetes mellitus (T2DM), chronic pancreatitis (CHP) and healthy controls. High performance liquid chromatography with UV detection (HPLC) was used to measure serum levels of retinol and ATRA in 246 patients with different stages of PDAC, T2DM, CHP and healthy controls. We found a significant decrease in the retinol concentration in PDAC (0.44 Significant decrease in retinol and ATRA levels in PDAC compared to T2DM, healthy individuals and/or CHP supports existing evidence of the role of retinoids in PDAC. However, neither ATRA nor retinol are suitable for detection of early PDAC. Correlation of ATRA levels and IGFBP-2 provides new information about a possible IGF and retinol relationship.

Identifiants

pubmed: 38058194
doi: 10.5507/bp.2023.049
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work.

Auteurs

Pavel Hrabak (P)

Fourth Department of Internal Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Miroslava Zelenkova (M)

Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.

Tomas Krechler (T)

Fourth Department of Internal Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Jan Soupal (J)

3rd Department of Medicine - Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Michal Vocka (M)

Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.

Tomas Hanus (T)

Department of Urology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.

Lubos Petruzelka (L)

Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.

Stepan Svacina (S)

3rd Department of Medicine - Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Ales Zak (A)

Fourth Department of Internal Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Tomas Zima (T)

Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.

Marta Kalousova (M)

Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.

Classifications MeSH